Cogent Bio granted FDA priority review for lead asset in tumor indication
Cogent Biosciences, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $34.96
-0.1% in 1d after detection
Post-detection moves
1h
+0.1%
1d
-0.1%
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS